Bianca M Liederer
Overview
Explore the profile of Bianca M Liederer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
1064
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Takahashi R, Malhi V, Liederer B, Cho S, Deng Y, Dean B, et al.
Drug Metab Dispos
. 2023 Jul;
51(10):1332-1341.
PMID: 37524543
Ipatasertib (GDC-0068) is a potent, highly selective, small-molecule inhibitor of protein kinase B (Akt) being developed by Genentech/Roche as a single agent and in combination with other therapies for the...
2.
Chan P, Ding H, Liederer B, Mao J, Belloni P, Chen L, et al.
Clin Transl Sci
. 2021 May;
14(5):1945-1954.
PMID: 34058071
GDC-0334 is a novel small molecule inhibitor of transient receptor potential cation channel member A1 (TRPA1), a promising therapeutic target for many nervous system and respiratory diseases. The pharmacokinetic (PK)...
3.
Sane R, Cheung K, Cho E, Liederer B, Hanover J, Malhi V, et al.
J Pharmacol Exp Ther
. 2021 May;
378(2):87-95.
PMID: 34049965
Ipatasertib is a pan-AKT inhibitor in development for the treatment of cancer. Ipatasertib was metabolized by CYP3A4 to its major metabolite, M1 (G-037720), and was a P-gp substrate and OATP1B1/1B3...
4.
Balestrini A, Joseph V, Dourado M, Reese R, Shields S, Rouge L, et al.
J Exp Med
. 2021 Feb;
218(4).
PMID: 33620419
Despite the development of effective therapies, a substantial proportion of asthmatics continue to have uncontrolled symptoms, airflow limitation, and exacerbations. Transient receptor potential cation channel member A1 (TRPA1) agonists are...
5.
Hanson J, Ma K, Elstrott J, Weber M, Saillet S, Khan A, et al.
Cell Rep
. 2020 Jan;
30(2):381-396.e4.
PMID: 31940483
NMDA receptors (NMDARs) play subunit-specific roles in synaptic function and are implicated in neuropsychiatric and neurodegenerative disorders. However, the in vivo consequences and therapeutic potential of pharmacologically enhancing NMDAR function...
6.
Ippen F, Grosch J, Subramanian M, Kuter B, Liederer B, Plise E, et al.
Neuro Oncol
. 2019 Jun;
21(11):1401-1411.
PMID: 31173106
Background: Activating mutations in the pathway of phosphatidylinositol-3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) occur in 43-70% of breast cancer brain metastasis patients. To date, the treatment of these patients...
7.
Patel S, Webster J, Varfolomeev E, Kwon Y, Cheng J, Zhang J, et al.
Cell Death Differ
. 2019 May;
27(1):161-175.
PMID: 31101885
The kinase RIP1 acts in multiple signaling pathways to regulate inflammatory responses and it can trigger both apoptosis and necroptosis. Its kinase activity has been implicated in a range of...
8.
Hamilton G, Chen H, Deshmukh G, Eigenbrot C, Fong R, Johnson A, et al.
Bioorg Med Chem Lett
. 2019 Apr;
29(12):1497-1501.
PMID: 31000154
Receptor-interacting protein kinase 1 (RIPK1), a key component of the cellular necroptosis pathway, has gained recognition as an important therapeutic target. Pharmacologic inhibition or genetic inactivation of RIPK1 has shown...
9.
Liederer B, Cheong J, Chou K, Dragovich P, Le H, Liang X, et al.
Xenobiotica
. 2018 Sep;
49(9):1063-1077.
PMID: 30257601
GNE-617 (-(4-((3,5-difluorophenyl)sulfonyl)benzyl)imidazo[1,2-]pyridine-6-carboxamide) is a potent, selective nicotinamide phosphoribosyltransferase (NAMPT) inhibitor being explored as a potential treatment for human cancers. Plasma clearance was low in monkeys and dogs (9.14 mL minkg...
10.
Daemen A, Liu B, Song K, Kwong M, Gao M, Hong R, et al.
Cell Metab
. 2018 Jul;
28(3):383-399.e9.
PMID: 30043751
The enzyme glutaminase (GLS1) is currently in clinical trials for oncology, yet there are no clear diagnostic criteria to identify responders. The evaluation of 25 basal breast lines expressing GLS1,...